PortalPublikationenThe use of HCT and/or ACE inhibitors significantly increases...

The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region

Standard

The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region. / Mehlan, Juliane; Ueberschaar, Julian; Hagenström, K; Garbe, C; Spitzer, M S; Druchkiv, V; Schuettauf, F.

in: GRAEF ARCH CLIN EXP, Jahrgang 260, Nr. 8, 08.2022, S. 2745-2751.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Mehlan, J, Ueberschaar, J, Hagenström, K, Garbe, C, Spitzer, MS, Druchkiv, V & Schuettauf, F 2022, 'The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region', GRAEF ARCH CLIN EXP, Jg. 260, Nr. 8, S. 2745-2751. https://doi.org/10.1007/s00417-022-05576-y

APA

Mehlan, J., Ueberschaar, J., Hagenström, K., Garbe, C., Spitzer, M. S., Druchkiv, V., & Schuettauf, F. (2022). The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region. GRAEF ARCH CLIN EXP, 260(8), 2745-2751. https://doi.org/10.1007/s00417-022-05576-y

Vancouver

Mehlan J, Ueberschaar J, Hagenström K, Garbe C, Spitzer MS, Druchkiv V et al. The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region. GRAEF ARCH CLIN EXP. 2022 Aug;260(8):2745-2751. https://doi.org/10.1007/s00417-022-05576-y

Bibtex

@article{a4c8d9a065a44fd7bdc2a428011e8e3d,
title = "The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region",
abstract = "BACKGROUND/AIMS: To investigate a possible association between the use of hydrochlorothiazide (HCT) and/or angiotensin-converting enzyme inhibitors (ACE inhibitors) and the occurrence of periocular non-melanoma skin cancer.METHODS: The files of 929 patients from the University Medical Center Hamburg-Eppendorf who were surgically treated for suspected periocular malignancy were evaluated retrospectively regarding the occurrence of non-melanoma skin cancer and concomitant medication. To be able to put the data in an overall context, we also analyzed age-matched routine data of the DAK-Gesundheit (DAK-G), a nationwide operating German health insurance company.RESULTS: Of the 929 patient records examined, who underwent surgical excision for suspected non-melanotic malignancy, non-melanocytic skin cancer could actually be determined by histology in 199 patients. In total, 176 patients (103 women, 72 men) had a basal cell carcinoma and 23 patients (16 women, 7 men) suffered from squamous cell carcinoma. The rate of intake of HCT or ACE inhibitors in our patient collective with non-melanotic skin cancer is significantly higher than in the general age-matched population (ORACE: 2.51, p < 0.001; ORHCT: 7.24, p < 0.001, ORBOTH: 4.61, p < 0.001).CONCLUSION: The rate of intake of HCT or ACE inhibitors is significantly higher in our patient collective with non-melanotic skin cancer compared to the group from the age-matched general population (DAK insured (p < 0.001)) compared to the routine data of the DAK-G. This leads us to the conclusion that taking the medication is associated with an increased risk for non-melanotic skin cancer. We recommend regular skin cancer screening, moderate ordination of photosensitizing medication, but above all comprehensive clarification of possible risks.",
author = "Juliane Mehlan and Julian Ueberschaar and K Hagenstr{\"o}m and C Garbe and Spitzer, {M S} and V Druchkiv and F Schuettauf",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = aug,
doi = "10.1007/s00417-022-05576-y",
language = "English",
volume = "260",
pages = "2745--2751",
journal = "GRAEF ARCH CLIN EXP",
issn = "0721-832X",
publisher = "Springer",
number = "8",

}

RIS

TY - JOUR

T1 - The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region

AU - Mehlan, Juliane

AU - Ueberschaar, Julian

AU - Hagenström, K

AU - Garbe, C

AU - Spitzer, M S

AU - Druchkiv, V

AU - Schuettauf, F

N1 - © 2022. The Author(s).

PY - 2022/8

Y1 - 2022/8

N2 - BACKGROUND/AIMS: To investigate a possible association between the use of hydrochlorothiazide (HCT) and/or angiotensin-converting enzyme inhibitors (ACE inhibitors) and the occurrence of periocular non-melanoma skin cancer.METHODS: The files of 929 patients from the University Medical Center Hamburg-Eppendorf who were surgically treated for suspected periocular malignancy were evaluated retrospectively regarding the occurrence of non-melanoma skin cancer and concomitant medication. To be able to put the data in an overall context, we also analyzed age-matched routine data of the DAK-Gesundheit (DAK-G), a nationwide operating German health insurance company.RESULTS: Of the 929 patient records examined, who underwent surgical excision for suspected non-melanotic malignancy, non-melanocytic skin cancer could actually be determined by histology in 199 patients. In total, 176 patients (103 women, 72 men) had a basal cell carcinoma and 23 patients (16 women, 7 men) suffered from squamous cell carcinoma. The rate of intake of HCT or ACE inhibitors in our patient collective with non-melanotic skin cancer is significantly higher than in the general age-matched population (ORACE: 2.51, p < 0.001; ORHCT: 7.24, p < 0.001, ORBOTH: 4.61, p < 0.001).CONCLUSION: The rate of intake of HCT or ACE inhibitors is significantly higher in our patient collective with non-melanotic skin cancer compared to the group from the age-matched general population (DAK insured (p < 0.001)) compared to the routine data of the DAK-G. This leads us to the conclusion that taking the medication is associated with an increased risk for non-melanotic skin cancer. We recommend regular skin cancer screening, moderate ordination of photosensitizing medication, but above all comprehensive clarification of possible risks.

AB - BACKGROUND/AIMS: To investigate a possible association between the use of hydrochlorothiazide (HCT) and/or angiotensin-converting enzyme inhibitors (ACE inhibitors) and the occurrence of periocular non-melanoma skin cancer.METHODS: The files of 929 patients from the University Medical Center Hamburg-Eppendorf who were surgically treated for suspected periocular malignancy were evaluated retrospectively regarding the occurrence of non-melanoma skin cancer and concomitant medication. To be able to put the data in an overall context, we also analyzed age-matched routine data of the DAK-Gesundheit (DAK-G), a nationwide operating German health insurance company.RESULTS: Of the 929 patient records examined, who underwent surgical excision for suspected non-melanotic malignancy, non-melanocytic skin cancer could actually be determined by histology in 199 patients. In total, 176 patients (103 women, 72 men) had a basal cell carcinoma and 23 patients (16 women, 7 men) suffered from squamous cell carcinoma. The rate of intake of HCT or ACE inhibitors in our patient collective with non-melanotic skin cancer is significantly higher than in the general age-matched population (ORACE: 2.51, p < 0.001; ORHCT: 7.24, p < 0.001, ORBOTH: 4.61, p < 0.001).CONCLUSION: The rate of intake of HCT or ACE inhibitors is significantly higher in our patient collective with non-melanotic skin cancer compared to the group from the age-matched general population (DAK insured (p < 0.001)) compared to the routine data of the DAK-G. This leads us to the conclusion that taking the medication is associated with an increased risk for non-melanotic skin cancer. We recommend regular skin cancer screening, moderate ordination of photosensitizing medication, but above all comprehensive clarification of possible risks.

U2 - 10.1007/s00417-022-05576-y

DO - 10.1007/s00417-022-05576-y

M3 - SCORING: Journal article

C2 - 35175408

VL - 260

SP - 2745

EP - 2751

JO - GRAEF ARCH CLIN EXP

JF - GRAEF ARCH CLIN EXP

SN - 0721-832X

IS - 8

ER -